The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Blockbuster Drugs: Endangered Species?
Our list of top-selling drugs of the 21st century shows how much money those drugs made between 2000 and 2011; the total amounts for all of them are in the billions. However, given the advent of personalized medicine and the increasing number of biosimilars entering the market, will pharmaceutical giants be able to maintain that level of success, or does our list contain the last of the blockbusters?